Syngene International

Stocks Available for F&O trade on NSE: Can Fin Homes, Dixon Technologies, Hindustan Aeronautics, Indian Energy Exchange, Indiamart Intermesh, IPCA Laboratories, MCX, OFSS, Polycab India and Syngene International are added to F&O segment

JSW Steel shares saw heavy volumes, a day after the company reported its earnings. Apollo Hospitals, HCC, and Syngene International were among other shares that saw high trading volumes today.

Shares of Biocon, Syngene's promoter company, also came under selling pressure due to this. Biocon shares fell as much as 1.76 per cent.

Excluding exceptional item, Biocon had posted a net profit of Rs 97 crore in September quarter of the previous year.

The company announced acquisition of the bio-informatics services of Strand Life Sciences along with a team of data scientists.

Shares of Syngene International jumped over 9 per cent on Thursday after the contract research company closed a deal with Bengaluru-based Strand Life Sciences to purchase the latter's assets related to systems biology, Heptox and pharma bioinformatics services.

Biocon's contract research arm Syngene International has established an integrated, multi-disciplinary drug discovery and development centre for Amgen in Bengaluru.

Biocon's contract research arm Syngene International has lined up $200 million (around Rs 1,342 crore) capex to bolster its manufacturing capabilities over the next three years.

Biocon's contract research and manufacturing arm Syngene International on Thursday reported a 28.32 per cent rise in standalone net profit at Rs 59.8 crore for the quarter ended June, 2016.

Biocon's contract research armSyngene International on Tuesday reported a 19.6 per cent rise instandalone net profit at Rs 66.5 crore for the March quarter.

Syngene International's net profit jumped 31 per cent annually to Rs 59 crore on sales of Rs 280 crore. In the year ago period it had reported a net profit of Rs 45 crore on revenues of Rs 228 crore.

Biocon's contract research arm - Syngene International - on Thursday reported a 31.25 per cent rise in net profit at Rs 58.8 crore for the third quarter of financial year 2015-16.

Syngene International, research arm of Biocon, on Monday appointed Jonathan Hunt as its CEO designate.

Syngene International, research arm of Biocon, posted 30.69 per cent rise in its net profit at Rs 52.29 crore for the second quarter ended September 30.

Some of the companies that are trading above their issue price include Navkar Corporation, Syngene International, PNC Infratech and VRL Logistics.

Stocks Available for F&O trade on NSE: Can Fin Homes, Dixon Technologies, Hindustan Aeronautics, Indian Energy Exchange, Indiamart Intermesh, IPCA Laboratories, MCX, OFSS, Polycab India and Syngene International are added to F&O segment

JSW Steel shares saw heavy volumes, a day after the company reported its earnings. Apollo Hospitals, HCC, and Syngene International were among other shares that saw high trading volumes today.

Shares of Biocon, Syngene's promoter company, also came under selling pressure due to this. Biocon shares fell as much as 1.76 per cent.

Excluding exceptional item, Biocon had posted a net profit of Rs 97 crore in September quarter of the previous year.

The company announced acquisition of the bio-informatics services of Strand Life Sciences along with a team of data scientists.

Shares of Syngene International jumped over 9 per cent on Thursday after the contract research company closed a deal with Bengaluru-based Strand Life Sciences to purchase the latter's assets related to systems biology, Heptox and pharma bioinformatics services.

Biocon's contract research arm Syngene International has established an integrated, multi-disciplinary drug discovery and development centre for Amgen in Bengaluru.

Biocon's contract research arm Syngene International has lined up $200 million (around Rs 1,342 crore) capex to bolster its manufacturing capabilities over the next three years.

Biocon's contract research and manufacturing arm Syngene International on Thursday reported a 28.32 per cent rise in standalone net profit at Rs 59.8 crore for the quarter ended June, 2016.

Biocon's contract research armSyngene International on Tuesday reported a 19.6 per cent rise instandalone net profit at Rs 66.5 crore for the March quarter.

Syngene International's net profit jumped 31 per cent annually to Rs 59 crore on sales of Rs 280 crore. In the year ago period it had reported a net profit of Rs 45 crore on revenues of Rs 228 crore.

Biocon's contract research arm - Syngene International - on Thursday reported a 31.25 per cent rise in net profit at Rs 58.8 crore for the third quarter of financial year 2015-16.

Syngene International, research arm of Biocon, on Monday appointed Jonathan Hunt as its CEO designate.

Syngene International, research arm of Biocon, posted 30.69 per cent rise in its net profit at Rs 52.29 crore for the second quarter ended September 30.

Some of the companies that are trading above their issue price include Navkar Corporation, Syngene International, PNC Infratech and VRL Logistics.